What is the acquisition price and premium offered by Merck KGaA for Bio-Techne, and how did the market react?

Merck KGaA agreed to acquire Bio-Techne Corp for $11.3 billion at an offer price of $73 per share, representing a 24% premium to Bio-Techne's closing share price on Wednesday; in response, Bio-Techne's shares rose 22% in premarket trading.

How will this acquisition strengthen Merck KGaA’s position in the life-science sector, and what does Bio-Techne supply?

The acquisition would expand Merck KGaA's presence in life-science research, as Bio-Techne supplies research reagents, proteins, antibodies, analytical instruments, and other tools used by scientists and drug developers.

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

Jun 25, 2026

Merck KGaA has agreed to acquire Bio-Techne Corp for $11.3 billion to expand its life-science research capabilities. The deal includes research reagents, proteins, and antibodies, funded via cash and debt.

reuters

Merck KGaA to Acquire Bio-Techne for Around $11 Billion

cen

2026-06-25

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

2026-06-26

Merck to Acquire US-Based Life Sciences Firm Bio-Techne for $11.3 Billion

2026-09-09

Merck KGaA Buys PostEra’s Oral Fertility Molecules

2026-10-19

Merck KGaA Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

FAQ